Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Blood

Volumn 115, Issue 25, 2010, Pages 5180-5190

  Stein, Rhona ^a   Gupta, Pankaj ^b   Chen, Xiaochuan ^a   Cardillo, Thomas M ^b   Furman, Richard R ^c   Chen, Susan ^a   Chang, Chien Hsing ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD20 ANTIGEN; CD22 ANTIGEN; CD74 ANTIGEN; CYCLOPHOSPHAMIDE; EPRATUZUMAB; FLUDARABINE; HLA DR ANTIGEN; IMMU 114; IMMUNOGLOBULIN G; JANUS KINASE; LABETUZUMAB; MILATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VELTUZUMAB; CYTOTOXIN; LEUKOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL LINE; CHRONIC DISEASE; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG BINDING; EAR DISEASE; FEMALE; HAIR CELL; HAIRY CELL LEUKEMIA; HLA SYSTEM; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SIGNAL TRANSDUCTION; STAINING; ANIMAL; BLOOD DISEASE; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; B-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXINS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEMATOLOGIC NEOPLASMS; HLA-DR ANTIGENS; HUMANS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID;

EID: 77954680142     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-228288     Document Type: Article

References (54)

1. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
2. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554-3561. (Pubitemid 34534522)
3. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445. (Pubitemid 24030569)
4. Altomonte M, Visintin A, Tecce R, et al. Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. J Cell Physiol. 2004;200(2):272-276. (Pubitemid 38880210)
5. Brozek CM, Savage SM, Marnell LL, Searles RP. Anti-DR antibodies inhibit in vitro production of human rheumatoid factor. J Clin Lab Immunol. 1990;31(3):105-109.
6. Rech J, Repp R, Rech D, et al. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk Lymphoma. 2006;47(10):2147-2154. (Pubitemid 44650092)
7. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side effects of rituximab treatment. Br J Haematol. 2001;115(4):807-811.
8. Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006;108(8):2736-2744
9. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol. 2001;38(1):1-8. (Pubitemid 32718637)
10. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
11. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104(12):3705-3711. (Pubitemid 39564448)
12. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004;10(8):2868-2878. (Pubitemid 38509167)
13. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol. 1995;32(17):1416-1427.
14. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res. 1995;55[suppl]:5935S-5945S.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1):55-63. (Pubitemid 14203433)
16. Lebedeva IV, Su ZZ, Sarkar D, et al. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res. 2003;63(23):8138-8144. (Pubitemid 37549460)
17. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273(29):18623-18632. (Pubitemid 28334795)
18. Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta. 2002;1589(3):311-316. (Pubitemid 34603302)
19. Carlo-Stella C, Di Nicola M, Turco MC, et al. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2006;66(3):1799-1808. (Pubitemid 43259966)
20. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561-1570. (Pubitemid 351413941)
21. Andersson LC, Nordling S, Häyry P. Proliferation of B and T cells in mixed lymphocyte cultures. J Exp Med. 1973;138(1):324-329.
22. Bellosillo B, Villamor N, López-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98(9):2771-2777.
23. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Practice. 2002;6(3):195-197.
24. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
25. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927-1932. (Pubitemid 28446681)
26. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002;117(4):828-834. (Pubitemid 34639243)
27. Gisselbrecht C. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. Br J Haematol. 2008;143(5):607-621.
28. Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol. 2008;45[suppl 2]:S11-S16.
29. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279-4284. (Pubitemid 36857789)
30. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-126.
31. Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008;67[suppl 3]:2-25.
32. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol. 2008;68(6):554-564.
33. Mariette X. Therapeutic potential for B-cell modulation in Sjögren's syndrome. Rheum Dis Clin North Am. 2008;34(4):1025-1033.
34. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87(6):345-364.
35. Roccatello D, Baldovino S, Alpa M, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol. 2008;26[suppl 49]:S67-S71.
36. Venkateshan SP, Sidhu S, Malhotra S, Pandhi P. Efficacy of biologicals in the treatment of rheumatoid arthritis: a meta-analysis. Pharmacology. 2009;83(1):1-9.
37. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry. 2003;52(2):101-109. (Pubitemid 37521508)
38. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112(13):4824-4831.
39. Czuczman M. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999;26(5)[suppl 14]:88-96. (Pubitemid 29523416)
40. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
41. Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol. 2007;44(6):1331-1341. (Pubitemid 44415959)
42. Stein R, Mattes MJ, Cardillo TM, et al. CD74: A new candidate target for the immunotherapy of hematological malignancies. Clin Cancer Res. 2007;13(18)[suppl]:5556S-5563S.
43. Shi JD, Bullock C, Hall WC, et al. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leuk Lymphoma. 2002;43(6):1303-1312. (Pubitemid 34537977)
44. Nagy Z, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002;8(8):801-807.
45. Newell MK, VanderWall J, Beard KS, Freed JH. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci U S A. 1993;90(22):10459-10463. (Pubitemid 23347061)
46. Truman JP, Choqueux C, Tschopp J, et al. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood. 1997;89(6):1996-2007. (Pubitemid 27132115)
47. Blancheteau V, Charron D, Mooney N. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum Immunol. 2002;63(5):375-383. (Pubitemid 34521369)
48. Drenou B, Blancheteau V, Burgess DH, Fauchet R, Charron DJ, Mooney NA. A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J Immunol. 1999;163(8):4115-4124. (Pubitemid 29474473)
49. Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood. 2004;103(5):1846-1854. (Pubitemid 38268982)
50. Chan-Hui PY, Weaver R. Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades. Biochem J. 1998;336(3):599-609. (Pubitemid 29008018)
51. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta. 1997;1333(2):F85-F104. (Pubitemid 27509073)
52. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene. 1999;18(45):6087-6093.
53. Sutherland CL, Heath AW, Pelech SL, Young PR, Gold MR. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J Immunol. 1996;157(8):3381-3390.
54. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays. 2000;22(9):818-826.